DK1492517T3 - Hotmelt-TTS til administration af rotigotin - Google Patents

Hotmelt-TTS til administration af rotigotin

Info

Publication number
DK1492517T3
DK1492517T3 DK03750403T DK03750403T DK1492517T3 DK 1492517 T3 DK1492517 T3 DK 1492517T3 DK 03750403 T DK03750403 T DK 03750403T DK 03750403 T DK03750403 T DK 03750403T DK 1492517 T3 DK1492517 T3 DK 1492517T3
Authority
DK
Denmark
Prior art keywords
tts
rotigotine
administration
matrix
hot melt
Prior art date
Application number
DK03750403T
Other languages
English (en)
Inventor
Hans-Michael Wolff
Armin Breitenbach
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Application granted granted Critical
Publication of DK1492517T3 publication Critical patent/DK1492517T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
DK03750403T 2002-07-30 2003-07-29 Hotmelt-TTS til administration af rotigotin DK1492517T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10234673A DE10234673B4 (de) 2002-07-30 2002-07-30 Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren

Publications (1)

Publication Number Publication Date
DK1492517T3 true DK1492517T3 (da) 2006-08-28

Family

ID=30469194

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03750403T DK1492517T3 (da) 2002-07-30 2003-07-29 Hotmelt-TTS til administration af rotigotin

Country Status (22)

Country Link
US (1) US9186335B2 (da)
EP (2) EP1492517B1 (da)
JP (1) JP4514608B2 (da)
KR (1) KR101041512B1 (da)
CN (1) CN100574755C (da)
AT (1) ATE324875T1 (da)
AU (1) AU2003269859B2 (da)
BR (1) BR0311437A (da)
CA (1) CA2494361C (da)
CY (1) CY1105138T1 (da)
DE (2) DE10234673B4 (da)
DK (1) DK1492517T3 (da)
ES (1) ES2263999T3 (da)
HK (1) HK1081436A1 (da)
IL (1) IL166070A0 (da)
MX (1) MXPA04012150A (da)
NO (1) NO20050835L (da)
PL (1) PL221308B1 (da)
PT (1) PT1492517E (da)
RU (1) RU2304434C2 (da)
WO (1) WO2004012721A2 (da)
ZA (1) ZA200500457B (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
DE10234673B4 (de) 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
US8173155B2 (en) * 2004-06-01 2012-05-08 Hisamitsu Pharmaceutical Co., Inc. Adhesive patch
JP4986411B2 (ja) * 2004-06-01 2012-07-25 久光製薬株式会社 貼付剤
EP1796610A4 (en) * 2004-09-29 2012-12-05 Schwarz Pharma Inc TRANSDERMAL THERAPEUTIC SYSTEM FOR PARKINSON DISEASE
DE102006026578B4 (de) 2006-06-08 2009-01-08 Lts Lohmann Therapie-Systeme Ag Wirkstoffpartikelhaltiges Transdermales Therapeutisches System mit erhöhtem Wirkstofffluss und Verfahren zu seiner Herstellung sowie Verwendung
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的2-胺基萘滿之於製造用於預防、減緩及/或治療各種類型疼痛之藥物上的用途
DE102006059462A1 (de) * 2006-12-14 2008-06-19 Henkel Kgaa Hot melt für Mikrowellen-Erwärmung
US20080226698A1 (en) * 2007-03-16 2008-09-18 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
WO2008146284A2 (en) 2007-05-30 2008-12-04 Chemagis Ltd. Crystalline rotigotine base and preparation process therefor
CN101147739B (zh) * 2007-07-06 2010-12-08 北京康倍得医药技术开发有限公司 含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂
CN101970422B (zh) * 2007-11-28 2014-10-22 Ucb制药有限公司 罗替高汀的多晶型物
US20100086582A1 (en) * 2008-10-06 2010-04-08 Mylan Technologies, Inc. Amorphous rotigotine transdermal system
DE102008060203A1 (de) 2008-12-07 2010-06-10 Dietrich Wilhelm Schacht Wirkstoffstabilisierende flächenförmige Vorrichtung
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
DE102009052972A1 (de) 2009-11-12 2011-09-15 Lts Lohmann Therapie-Systeme Ag Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm
HUE039447T2 (hu) * 2009-12-22 2018-12-28 Ucb Biopharma Sprl Polivinilpirrolidon rotigotin nem kristályos formája szilárd diszperziójának stabilizálására
EP2544667B1 (en) * 2010-03-09 2018-11-14 Alkermes Pharma Ireland Limited Alcohol resistant enteric pharmaceutical compositions
AU2011334494B2 (en) * 2010-11-25 2015-11-05 Geneora Pharma (Shijiazhuang) Co., Ltd. Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative
WO2012084969A1 (en) 2010-12-22 2012-06-28 Hexal Ag Adhesive composition containing rotigotine and transdermal therapeutic system comprising the adhesive composition
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
JP5856424B2 (ja) * 2011-10-05 2016-02-09 祐徳薬品工業株式会社 ロチゴチン含有経皮吸収型貼付剤
WO2013075823A1 (en) 2011-11-22 2013-05-30 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermal therapeutic system comprising rotigotine and crystallization inhibitor
DE102011119043A1 (de) 2011-11-22 2013-05-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TDS) mit Rotigotin
DE102012013421A1 (de) 2012-07-03 2014-01-09 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TTS) mit Rotigotin
DE102012013439A1 (de) 2012-07-03 2014-01-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor
DE102011090178A1 (de) 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
JP6180520B2 (ja) * 2012-07-05 2017-08-16 エスケー ケミカルス カンパニー リミテッド ロチゴチンを含有した経皮吸収製剤(Transdermalcompositioncomprisingrotigotine)
KR101558043B1 (ko) * 2012-07-06 2015-10-07 에스케이케미칼주식회사 로티고틴 함유 경피흡수제제
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片
WO2014193190A1 (ko) * 2013-05-30 2014-12-04 에스케이케미칼 (주) 로티고틴과 지방산 및 스티렌 점착제를 함유한 경피치료시스템
WO2014198422A1 (de) * 2013-06-14 2014-12-18 Tesa Labtec Gmbh Transdermales therapiesystem (tts) mit rotigotin
WO2014198423A1 (de) * 2013-06-14 2014-12-18 Tesa Labtec Gmbh Dreischichtiges transdermales therapiesystem (tts)
EP3010545A2 (en) * 2013-06-20 2016-04-27 Mylan Technologies, Inc. Storage stable transdermal patch of rotigotine
CA2916183C (en) 2013-07-03 2022-03-29 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system with electronic component
EP3145503A1 (en) 2014-05-20 2017-03-29 LTS Lohmann Therapie-Systeme AG Method for adjusting the release of active agent in a transdermal delivery system
WO2015177204A1 (en) 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
CA2948221C (en) 2014-05-20 2022-11-22 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
KR102364378B1 (ko) 2014-05-21 2022-02-16 에스케이케미칼 주식회사 안정성을 향상시킨 로티고틴 함유 경피흡수제제
WO2019234662A1 (en) * 2018-06-07 2019-12-12 Nal Pharmaceutical Group Limited Transdermal drug delivery system containing rotigotine
KR20200046461A (ko) * 2018-10-24 2020-05-07 에스케이케미칼 주식회사 비결정 로티고틴 함유 조성물 및 이의 제조 방법
KR102260202B1 (ko) * 2019-10-30 2021-06-03 에바바이오 주식회사 로티고틴 공융 혼합물 및 이의 용도
PL3854388T3 (pl) 2020-01-24 2024-02-26 Luye Pharma Switzerland Ag Transdermalny system terapeutyczny z substancją czynną rotygotyną i co najmniej jednym klejem silikonowym nieodpornym na działanie amin

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US36754A (en) * 1862-10-21 Improvement in watch-chain guards or keys
US4144317A (en) 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US5177112A (en) 1983-01-03 1993-01-05 Whitby Research, Inc. Substituted 2-aminotetralins
US4655767A (en) 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
US4880633A (en) 1986-03-12 1989-11-14 Merck & Co., Inc. Transdermal drug delivery system
US4863970A (en) 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
DE3743945A1 (de) * 1987-09-01 1989-03-09 Lohmann Gmbh & Co Kg Vorrichtung zur abgabe von stoffen, verfahren zu ihrer herstellung sowie ihre verwendung
US5273757A (en) 1987-09-01 1993-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Apparatus for the delivery of substances, processes for the production thereof and use thereof
US4915950A (en) 1988-02-12 1990-04-10 Cygnus Research Corporation Printed transdermal drug delivery device
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
DE3827561C1 (da) 1988-08-13 1989-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US4865920A (en) 1988-09-20 1989-09-12 Dow Corning Corporation Hot-melt pressure sensitive adhesive article and method of making
US4973468A (en) 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
FR2648131B1 (fr) 1989-06-13 1991-10-18 Oreal Nouveaux derives de tetrahydro -5,6,7,8 naphtalenol-1, leur procede de preparation et leur utilisation en tant qu'agents antioxydants dans des compositions cosmetiques et pharmaceutiques les contenant
US5252335A (en) 1989-07-12 1993-10-12 Cygnus Therapeutic Systems Transdermal administration of lisuride
US5091186A (en) 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
US5124157A (en) 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5252334A (en) 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
US5271940A (en) 1989-09-14 1993-12-21 Cygnus Therapeutic Systems Transdermal delivery device having delayed onset
DE3933460A1 (de) 1989-10-06 1991-04-18 Lohmann Therapie Syst Lts Oestrogenhaltiges wirkstoffpflaster
US5147916A (en) * 1990-02-21 1992-09-15 Dow Corning Corporation Hot-melt silicone pressure sensitive adhesive composition and related methods and articles
US5246997A (en) * 1990-02-21 1993-09-21 Dow Corning Corporation Method of making a hot-melt silicone pressure sensitive adhesive-coated substrate
US5069909A (en) 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5300299A (en) * 1991-07-22 1994-04-05 Dow Corning Corporation Silicone pressure sensitive adhesive containing alkylmethylsiloxane wax and related methods and devices
US5328696A (en) * 1991-07-22 1994-07-12 Dow Corning Corporation Devices using silicone pressure sensitive adhesives containing organic wax
US5234690A (en) 1991-08-23 1993-08-10 Cygnus Therapeutic Systems Transdermal drug delivery device using an unfilled microporous membrane to achieve delayed onset
US5273756A (en) 1991-08-23 1993-12-28 Cygnus Therapeutic Systems Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset
US5273755A (en) 1991-08-23 1993-12-28 Cygnus Therapeutic Systems Transdermal drug delivery device using a polymer-filled microporous membrane to achieve delayed onset
US5225198A (en) 1991-08-27 1993-07-06 Cygnus Therapeutic Systems Transdermal administration of short or intermediate half-life benzodiazepines
CA2115840A1 (en) 1991-08-27 1993-03-04 Tsung-Min Hsu Transdermal formulation for administering prazosin
JPH05208907A (ja) * 1991-09-17 1993-08-20 Sekisui Chem Co Ltd 消炎鎮痛貼付剤
AU2782592A (en) 1991-10-15 1993-05-21 Cygnus Therapeutic Systems Thermal enhancement of transdermal drug administration
AU3595393A (en) 1992-01-31 1993-09-01 Cygnus Therapeutic Systems Transdermal administration of buprenorphine in the form of ion pair complexes
GB9202915D0 (en) 1992-02-12 1992-03-25 Wellcome Found Chemical compounds
DE4224325C1 (de) 1992-07-23 1994-02-10 Sanol Arznei Schwarz Gmbh Wirkstoffpflaster für niedrigschmelzende und/oder flüchtige Wirkstoffe und Verfahren zu seiner Herstellung
EP0656771A4 (en) 1992-08-25 1996-07-31 Cygnus Therapeutic Systems DEVICE FOR TRANSDERMAL DRUG DELIVERY.
US5308625A (en) 1992-09-02 1994-05-03 Cygnus Therapeutic Systems Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters
US5989586A (en) 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
DE4301781C2 (de) * 1993-01-23 1995-07-20 Lohmann Therapie Syst Lts Nitroglycerinhaltiges Pflaster, Verfahren zu seiner Herstellung und Verwendung
AU7172794A (en) 1993-06-24 1995-01-17 Cygnus Therapeutic Systems Transdermal delivery system package
JPH09503997A (ja) 1993-07-08 1997-04-22 シグナス,インコーポレイテッド モノリシックなマトリックス経皮送達システム
US5382596A (en) 1993-08-05 1995-01-17 Whitby Research, Inc. Substituted 2-aminotetralins
US5554381A (en) 1993-08-09 1996-09-10 Cygnus, Inc. Low flux matrix system for delivering potent drugs transdermally
WO1995005137A1 (en) 1993-08-16 1995-02-23 Cygnus Therapeutic Systems Transdermal delivery system using a combination of permeation enhancers
WO1995005138A1 (en) 1993-08-16 1995-02-23 Cygnus Therapeutic Systems Contact adhesive extends wear time on skin
US5482988A (en) 1994-01-14 1996-01-09 Dow Corning Corporation Hot-melt silicone pressure sensitive adhesive with siloxylated polyether waxes as additives
JPH08510572A (ja) 1994-03-11 1996-11-05 フィリップス エレクトロニクス エヌ ベー 準周期的信号用の送信システム
DE69519023T2 (de) 1994-06-24 2001-06-13 Cygnus Therapeutic Systems Einrichtung zur iontophoretischen probennahme
US5771890A (en) 1994-06-24 1998-06-30 Cygnus, Inc. Device and method for sampling of substances using alternating polarity
US6024974A (en) 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs
WO1996022083A1 (en) 1995-01-19 1996-07-25 Cygnus, Inc. POLYISOBUTYLENE ADHESIVES CONTAINING HIGH Tg TACKIFIER FOR TRANSDERMAL DEVICES
WO1996022084A2 (en) 1995-01-19 1996-07-25 Cygnus, Inc. Polymer adhesive formulation containing sorbent particles
US5601839A (en) 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
GB9511366D0 (en) 1995-06-06 1995-08-02 Smithkline Beecham Plc Novel formulations
AU6032696A (en) 1995-06-07 1996-12-30 Cygnus Therapeutic Systems Pressure sensitive acrylate adhesive composition cross-linke d with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group
US5785991A (en) 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
DK0836506T4 (da) 1995-06-07 2012-01-30 Ortho Mcneil Pharm Inc Transdermalt plaster til indgivelse af 17-deacetyl norgestimat alene eller i kombination med et østrogen
US5559165A (en) 1995-08-08 1996-09-24 National Starch And Chemical Investment Holding Corporation Hot melt adhesives for bonding to sensitive areas of the human body
US5906830A (en) 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US5902603A (en) 1995-09-14 1999-05-11 Cygnus, Inc. Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use
US5891461A (en) 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
AU7238896A (en) 1995-09-14 1997-04-01 Cygnus, Inc. High capacity, superabsorbent drug reservoirs for use in transdermal drug delivery systems
US6063398A (en) 1995-09-20 2000-05-16 L'oreal Cosmetic or dermopharmaceutical patch containing, in an anhydrous polymeric matrix, at least one active compound which is, in particular, unstable in oxidizing mediums, and at least one water-absorbing agent
US5807570A (en) 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
US5733571A (en) 1995-12-08 1998-03-31 Euro-Celtique, S.A. Transdermal patch for comparative evaluations
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5843472A (en) 1997-02-28 1998-12-01 Cygnus, Inc. Transdermal drug delivery sytem for the administration of tamsulosin, and related compositions and methods of use
US5879701A (en) 1997-02-28 1999-03-09 Cygnus, Inc. Transdermal delivery of basic drugs using nonpolar adhesive systems and acidic solubilizing agents
DE19814083C2 (de) * 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
ATE220936T1 (de) 1998-05-13 2002-08-15 Cygnus Therapeutic Systems Sammelvorrichtungen für transdermale probennahmesysteme
DE19821788C1 (de) 1998-05-15 1999-12-02 Sanol Arznei Schwarz Gmbh Transdermales Therapeutisches System (TTS) Pergolid enthaltend
DE19828273B4 (de) 1998-06-25 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System, enthaltend Hormone und Kristallisationsinhibitoren
JP2002524178A (ja) 1998-09-17 2002-08-06 シグナス, インコーポレイテッド ゲル/センサアセンブリ用のプレス装置
JP2002541094A (ja) 1999-04-01 2002-12-03 アルザ・コーポレーション ポリウレタン薬物貯蔵部を含んでなる経皮薬物送達装置
FR2792529B1 (fr) 1999-04-26 2001-09-28 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
WO2000074661A2 (en) 1999-06-05 2000-12-14 Noven Pharmaceuticals, Inc. Solubility enhancement of drugs in transdermal drug delivery systems and methods of use
US6218421B1 (en) 1999-07-01 2001-04-17 Smithkline Beecham P.L.C. Method of promoting smoking cessation
DE19958554C2 (de) * 1999-07-02 2002-06-13 Lohmann Therapie Syst Lts Mikroreservoirsystem auf Basis von Polysiloxanen und ambiphilen Lösemitteln und ihre Herstellung
DE19940238A1 (de) 1999-08-25 2001-03-01 Lohmann Therapie Syst Lts Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten
AU1613101A (en) 1999-11-23 2001-06-04 Aderis Pharmaceuticals, Inc. Improved process for preparing nitrogen-substituted aminotetralins
ATE245972T1 (de) 1999-11-29 2003-08-15 Lohmann Therapie Syst Lts Transdermale therapeutische systeme mit verbesserter stabilität und ein verfahren zu ihrer herstellung
US20020110585A1 (en) 1999-11-30 2002-08-15 Godbey Kristin J. Patch therapeutic agent delivery device having texturized backing
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10041479A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
US20020119187A1 (en) 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DE10060550C1 (de) 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
DK1256340T3 (da) * 2001-05-08 2003-12-01 Sanol Arznei Schwarz Gmbh Forbedret transdermalt, terapeutisk system til behandlingen af Parkinsons sygdom
US20030027793A1 (en) 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
US20030026830A1 (en) 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
FR2829028B1 (fr) 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
US20060263419A1 (en) 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
US20040034083A1 (en) 2002-04-18 2004-02-19 Stephenson Diane T. Combination therapy for the treatment of Parkinson's disease with cyclooxygenase-2 (COX2) inhibitor(s)
US20040048779A1 (en) 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US20060216336A1 (en) 2002-05-07 2006-09-28 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
EA009024B1 (ru) * 2002-06-25 2007-10-26 АКРУКС ДиДиЭс ПиТиУай ЭлТиДи Фармацевтическая композиция для чрескожной доставки активного агента (варианты)
US8211462B2 (en) 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
DE10234673B4 (de) 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US8246980B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
DK1426049T3 (da) 2002-12-02 2005-08-22 Sanol Arznei Schwarz Gmbh Iontophoretisk tilförsel af rotigotin til behandling af Parkinsons sygdom
US9102726B2 (en) 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en) 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
TWI392670B (zh) 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的2-胺基萘滿之於製造用於預防、減緩及/或治療各種類型疼痛之藥物上的用途
EP1987815A1 (en) 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
CN101970422B (zh) 2007-11-28 2014-10-22 Ucb制药有限公司 罗替高汀的多晶型物
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
HUE039447T2 (hu) 2009-12-22 2018-12-28 Ucb Biopharma Sprl Polivinilpirrolidon rotigotin nem kristályos formája szilárd diszperziójának stabilizálására

Also Published As

Publication number Publication date
PT1492517E (pt) 2006-09-29
JP2006508908A (ja) 2006-03-16
DE10234673A1 (de) 2004-02-19
AU2003269859A1 (en) 2004-02-23
JP4514608B2 (ja) 2010-07-28
US9186335B2 (en) 2015-11-17
CY1105138T1 (el) 2009-11-04
NO20050835L (no) 2005-02-16
EP1669063A1 (de) 2006-06-14
PL221308B1 (pl) 2016-03-31
MXPA04012150A (es) 2005-09-21
ES2263999T3 (es) 2006-12-16
RU2005105684A (ru) 2005-11-20
CA2494361C (en) 2010-11-02
RU2304434C2 (ru) 2007-08-20
CA2494361A1 (en) 2004-02-12
CN1671364A (zh) 2005-09-21
WO2004012721A2 (de) 2004-02-12
WO2004012721A3 (de) 2004-04-08
KR101041512B1 (ko) 2011-06-16
KR20050038007A (ko) 2005-04-25
BR0311437A (pt) 2005-03-22
IL166070A0 (en) 2006-01-15
ATE324875T1 (de) 2006-06-15
EP1492517B1 (de) 2006-05-03
EP1492517A2 (de) 2005-01-05
ZA200500457B (en) 2005-08-31
DE10234673B4 (de) 2007-08-16
CN100574755C (zh) 2009-12-30
HK1081436A1 (en) 2006-05-19
US20050260254A1 (en) 2005-11-24
DE50303201D1 (de) 2006-06-08
PL374852A1 (en) 2005-11-14
AU2003269859B2 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
DK1492517T3 (da) Hotmelt-TTS til administration af rotigotin
EA200501420A1 (ru) Устройство доставки для лекарственной и клеточной терапии
NO20043871L (no) Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid
HRP20050077B1 (hr) Postupci i oblici doziranja za kontrolirano oslobađanje paliperidona
MX2009013574A (es) Formas de dosificacion solidas o semisolidas de liberacion modificada.
MXPA03006217A (es) Sistema de administracion espaciada de farmacos.
WO2010056302A3 (en) Iontophoretic therapeutic agent delivery system
WO2004056311A3 (en) Stimuli-responsive systems for controlled drug delivery
TW570815B (en) Transdermal therapeutic system (TTS) containing the active substance fentanyl
WO2008062440A3 (en) Programmable buoyant delivery technology
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
WO2008013929A3 (en) Anti-migraine oral spray formulations and methods
AU2003215657A1 (en) Hormone-containing transdermal therapeutic system with an active substance reservoir based on vinylacetate-vinylpyrrolidone copolymer with improved cohesion.
EA200601129A1 (ru) Способ лечения нежелательного эффекта при чрескожной доставке лекарства (варианты)
HRP20180327T1 (hr) Sredstva za uporabu u slučaju intolerancije na fruktozu
CO5640120A2 (es) Formulacion y metodods para el tratamiento de trombocitemia
IN2012DN01225A (da)
DK1450773T3 (da) Transdermalt terapeutisk system med forbedret langvarig bærekomfort
WO2004098537A3 (en) Activation agents on the surface of encapsulation vesicles
GB2446341A (en) Method and system for transdermal drug delivery
WO2008051527A3 (en) Sustained release of agents for localized pain management
ATE326947T1 (de) Thixotropes nasenspray
WO2006016351A3 (en) Drug delivery in the coronary sinus
TW200719902A (en) Solid transdermal therapeutic system with uv absorber
WO2006113796A3 (en) Microbial cellulose materials for use in transdermal drug delivery system